eFFECTOR Therapeutics- Warrants (26/08/2026) EBIT

The latest EBIT for EFTRW is $-610K as of June 2026. That compares with $-25M in the prior-year period — up 97.6% year over year. That is below the Healthcare sector average of $23B. Investors often review this figure alongside eFFECTOR Therapeutics- Warrants (26/08/2026)'s historical trend and sector peers before judging valuation or financial health.

Over the past year, EFTRW's EBIT moved from $-25M to $-610K — a 97.6% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in eFFECTOR Therapeutics- Warrants (26/08/2026)'s operating scale or balance-sheet position.

Against Healthcare companies, EFTRW currently prints $-610K for EBIT, while the sector average sits near $23B. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at eFFECTOR Therapeutics- Warrants (26/08/2026)'s growth, margins, and balance sheet.

A EBIT figure of $-610K for EFTRW is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $23B. Explore the charts below for those layers of context.

After noting EFTRW's EBIT ($-610K), review year-over-year change from $-25M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.